MX2023003459A - Nuevos compuestos. - Google Patents
Nuevos compuestos.Info
- Publication number
- MX2023003459A MX2023003459A MX2023003459A MX2023003459A MX2023003459A MX 2023003459 A MX2023003459 A MX 2023003459A MX 2023003459 A MX2023003459 A MX 2023003459A MX 2023003459 A MX2023003459 A MX 2023003459A MX 2023003459 A MX2023003459 A MX 2023003459A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- new compounds
- nlrp3
- inflammasone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a compuestos novedosos para su uso como inhibidores de la producción del inflamosoma NLRP3, en donde tales compuestos son como se definen mediante los compuestos de fórmula (I) (ver Fórmula) (I) y en donde los componentes integrantes R1, R2 y R3 se definen en la descripción, y donde los compuestos pueden ser útiles como medicamentos, por ejemplo, para su uso en el tratamiento de una enfermedad o trastorno que está asociado con la actividad del inflamosoma NLRP3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382846 | 2020-09-24 | ||
PCT/EP2021/076199 WO2022063896A1 (en) | 2020-09-24 | 2021-09-23 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003459A true MX2023003459A (es) | 2023-04-19 |
Family
ID=72709315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003459A MX2023003459A (es) | 2020-09-24 | 2021-09-23 | Nuevos compuestos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240043450A1 (es) |
EP (1) | EP4217347A1 (es) |
JP (1) | JP2023542205A (es) |
KR (1) | KR20230074528A (es) |
CN (1) | CN116194445A (es) |
AU (1) | AU2021346847A1 (es) |
CA (1) | CA3189887A1 (es) |
MX (1) | MX2023003459A (es) |
WO (1) | WO2022063896A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL314035A (en) * | 2022-01-07 | 2024-09-01 | Nodthera Ltd | Bicyclic phthalazine-1(2H)-one derivatives and related uses |
TW202416965A (zh) * | 2022-08-29 | 2024-05-01 | 日商日本煙草產業股份有限公司 | 吡唑并嘧啶化合物及其醫藥用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017612B2 (en) * | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
EP3697758B1 (en) | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
US20220098188A1 (en) | 2018-08-17 | 2022-03-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors |
-
2021
- 2021-09-23 AU AU2021346847A patent/AU2021346847A1/en active Pending
- 2021-09-23 WO PCT/EP2021/076199 patent/WO2022063896A1/en active Application Filing
- 2021-09-23 US US18/245,794 patent/US20240043450A1/en active Pending
- 2021-09-23 JP JP2023518345A patent/JP2023542205A/ja active Pending
- 2021-09-23 KR KR1020237013635A patent/KR20230074528A/ko unknown
- 2021-09-23 CA CA3189887A patent/CA3189887A1/en active Pending
- 2021-09-23 MX MX2023003459A patent/MX2023003459A/es unknown
- 2021-09-23 EP EP21778506.2A patent/EP4217347A1/en active Pending
- 2021-09-23 CN CN202180064526.4A patent/CN116194445A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116194445A (zh) | 2023-05-30 |
WO2022063896A1 (en) | 2022-03-31 |
CA3189887A1 (en) | 2022-03-31 |
KR20230074528A (ko) | 2023-05-30 |
AU2021346847A1 (en) | 2023-06-08 |
EP4217347A1 (en) | 2023-08-02 |
US20240043450A1 (en) | 2024-02-08 |
JP2023542205A (ja) | 2023-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014942A (es) | Nuevos compuestos. | |
MX2022013637A (es) | Nuevos compuestos de triazinoindol. | |
MX2022012896A (es) | Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3. | |
MX2022013323A (es) | Compuestos triciclicos como inhibidores de nlrp3. | |
MX2022012897A (es) | Pirazolo[1,5-d][1,2,4]triazin-5(4h)acetamidas como inhibidores de la ruta del inflamasoma nlrp3. | |
CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
MX2023003459A (es) | Nuevos compuestos. | |
NO20072895L (no) | Topiske sammensetninger inneholdende myrica gale olje | |
MX2009009623A (es) | Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide. | |
BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
MX2023014722A (es) | Forma cristalina de tolebrutinib y método de preparación y su uso. | |
MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
MX2023006578A (es) | Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas. | |
MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
MX2023003458A (es) | Nuevos compuestos. | |
MX2023003825A (es) | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. | |
MX2023014891A (es) | 5-oxo-pirido [2,3-d]piriidazin-6(5h)-ilo acetamidas. | |
MX2023012840A (es) | Derivados de ftalazinona como inhibidores del inflamasoma nlrp3. | |
MX2023010310A (es) | Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3. | |
MX2023010223A (es) | Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3. | |
TNSN06233A1 (en) | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments | |
MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
MX2023004955A (es) | Compuestos de aminotiazol deuterados como compuestos antiviricos. |